Cytoo
Preclinical stage drug discovery company specialized in muscular and neuromuscular disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
$40—60m (Dealroom.co estimates Nov 2011.)
Company register number 504844168
Grenoble Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 1.1m | 1.9m | 2.3m | 4.6m | 6.4m | 7.5m |
| % growth | (21 %) | 42 % | 71 % | 24 % | 95 % | 41 % | 16 % |
| EBITDA | (1.2m) | (<1m) | <1m | <1m | 1.9m | - | - |
| % EBITDA margin | (157 %) | (74 %) | 7 % | 14 % | 42 % | - | - |
| Profit | (<1m) | (<1m) | <1m | <1m | 2.4m | - | - |
| % profit margin | (119 %) | (57 %) | 19 % | 8 % | 53 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | €1.0m | Seed | |
$4.7m | Series B | ||
$10.0m | Series C | ||
| Total Funding | $15.8m | ||
Recent News about Cytoo
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.